Noile-Immune BiotechTSE:4893 +0.84%54 Piotroski F-Score is 4 as of Jun. 28, 2026, which is at its 10-year median of 4.00. GuruFocus rates TSE:4893 with a GF Score™ of 54/100 and a GF Value™ of 円4.38 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,340 Biotechnology companies, Noile-Immune Biotech ranks better than 74.18% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Noile-Immune Biotech has an F-score of 4 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Noile-Immune Biotech's Piotroski F-Score or its related term are showing as below:
TSE:4893'
s Piotroski F-Score Range Over the Past 10 Years
Min: 4 Med: 4 Max: 6
Current: 4
During the past 6 years, the highest Piotroski F-Score of Noile-Immune Biotech was 6. The lowest was 4. And the median was 4.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Noile-Immune Biotech Piotroski F-Score Related Terms
Noile-Immune Biotech Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Noile-Immune Biotech's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4893 vs VRTX, REGN, ALNY: Piotroski F-Score Comparison
For the Biotechnology subindustry, Noile-Immune Biotech's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Noile-Immune Biotech Piotroski F-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Noile-Immune Biotech's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Noile-Immune Biotech's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Noile-Immune Biotech's current Net Income (TTM) was -793.54.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Noile-Immune Biotech's current Cash Flow from Operations (TTM) was -752.22.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Noile-Immune Biotech's return on assets of this year was -0.16531408. Noile-Immune Biotech's return on assets of last year was -0.16689116.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Noile-Immune Biotech's gearing of this year was 0. Noile-Immune Biotech's gearing of last year was 0.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Noile-Immune Biotech's current ratio of this year was 53.53726228. Noile-Immune Biotech's current ratio of last year was 68.76882533.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Noile-Immune Biotech's number of shares in issue this year was 43.302. Noile-Immune Biotech's number of shares in issue last year was 43.298.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Noile-Immune Biotech's gross margin of this year was 1. Noile-Immune Biotech's gross margin of last year was 0.97429814.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Noile-Immune Biotech's asset turnover of this year was 0.00104163. Noile-Immune Biotech's asset turnover of last year was 0.00131287.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
0
+
1
+
1
+
1
+
0
+
0
+
1
+
0
=
4
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Noile-Immune Biotech has an F-score of 4 indicating the company's financial situation is typical for a stable company.
Noile-Immune Biotech (TSE:4893) has a Piotroski F-Score of 4 as of Jun. 28, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Noile-Immune Biotech and its competitors. This is near median its historical median of 4.00. Over the past decade, Noile-Immune Biotech's Piotroski F-Score has ranged from 4.00 to 6.00. According to the industry distribution chart, Noile-Immune Biotech ranks #346 out of 1340 companies in the Biotechnology industry, placing it in the top 25.8%.
Is Noile-Immune Biotech's Piotroski F-Score too high?
Noile-Immune Biotech's current Piotroski F-Score of 4 is near median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 6.00. The Biotechnology industry median Piotroski F-Score is 3.00. Noile-Immune Biotech's value of 4 is 33.3% above this industry median. Based on the distribution chart, Noile-Immune Biotech ranks #346 out of 1340 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Noile-Immune Biotech has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noile-Immune Biotech's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Noile-Immune Biotech ranks #346 out of 1340 companies for Piotroski F-Score. This puts Noile-Immune Biotech in the upper half of its industry. The industry median Piotroski F-Score is 3.00. Noile-Immune Biotech's value of 4 is 33.3% above this benchmark. Historically, Noile-Immune Biotech's own Piotroski F-Score has ranged from 4.00 to 6.00 over the past decade. While the company's 10-year median is 4.00 vs. the industry median of 3.00, Noile-Immune Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,340 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Noile-Immune Biotech's current Piotroski F-Score of 4 is 33.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Noile-Immune Biotech and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Noile-Immune Biotech's current Piotroski F-Score is 4, which is near median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noile-Immune Biotech stock overvalued right now?
Based on GuruFocus' analysis, Noile-Immune Biotech (TSE:4893) is currently considered Significantly Overvalued. The stock's GF Value™ is 円4.38, compared to a current price of 円120.00 — trading 2639.7% above its estimated fair value. The current Piotroski F-Score is 4, which is near median its 10-year median of 4.00 and 33.3% above the Biotechnology industry median of 3.00. Noile-Immune Biotech's overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Noile-Immune Biotech (TSE:4893), the current Piotroski F-Score is 4 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Noile-Immune Biotech (TSE:4893) Overvalued in 2026?
Based on GuruFocus' analysis, Noile-Immune Biotech stock appears to be overvalued.
The current stock price of 円120.00 is trading 2639.7% above its estimated GF Value™ of 円4.38.
GuruFocus considers Noile-Immune Biotech to be Significantly Overvalued.
Key valuation signals for TSE:4893:
Piotroski F-Score: 4 (near median its 10-year median of 4.00)
GF Value™: 円4.38 vs. price of 円120.00 (2639.7% above fair value)
Industry Position: 33.3% above the Biotechnology median (#346 of 1340)
No single metric tells the full story. See the TSE:4893 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Noile-Immune Biotech Inc is engaged in the development of CAR-T cell therapy for solid cancers using its proprietary technology. The company's development pipeline and collaborative projects with other companies include different product candidates such as NIB102, NIB103, NIB104, ADAP01, AUTL01, etc. It operates in a single segment, the cancer immunotherapy drug discovery business.
54GF Score
Get the complete analysis for TSE:4893
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4893 has been successfully added to your 
